12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Prevnar 13 regulatory update

FDA approved expanding the label of Prevnar 13 from Pfizer to include prevention of invasive disease caused by the 13 serotypes of Streptococcus pneumoniae contained within the vaccine in subjects ages 6-17 years. The pneumococcal vaccine is already...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >